The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1415
April 29, 2013
View Complete Issue         Table of Contents 2019 
Icosapent Ethyl (Vascepa) for Severe Hypertriglyceridemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Icosapent Ethyl (Vascepa) for Severe Hypertriglyceridemia
April 29, 2013 (Issue: 1415)
Icosapent ethyl (Vascepa [vas EE puh] – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA as an adjunct to diet for treatment of severe hypertriglyceridemia (≥500 mg/dL). Vascepa is the second omega-3...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Icosapent Ethyl (Vascepa) for Severe Hypertriglyceridemia
Article code: 1415a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.